search
Back to results

The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance

Primary Purpose

AMPD, Ischemic Tolerance

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
systemic administration of 99mTc-HYNIC-Annexin A5
10 minutes of ischemic handgripping
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for AMPD

Eligibility Criteria

18 Years - 40 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: male 18-40 years healthy AMPD1 34C>T variant (heterozygous) or matched control Exclusion Criteria: cardiovascular / pulmonary disease diabetes / hypertension

Sites / Locations

    Outcomes

    Primary Outcome Measures

    99mTc-Annexin A5 targeting

    Secondary Outcome Measures

    Full Information

    First Posted
    April 27, 2006
    Last Updated
    April 21, 2016
    Sponsor
    Radboud University Medical Center
    Collaborators
    ZonMw: The Netherlands Organisation for Health Research and Development
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00319059
    Brief Title
    The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
    Official Title
    The Influence of the 34C>T Variant in the AMPD1 Gene on Individual Susceptibility for Ischemia-reperfusion.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2006 (undefined)
    Primary Completion Date
    April 2006 (Actual)
    Study Completion Date
    April 2006 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Radboud University Medical Center
    Collaborators
    ZonMw: The Netherlands Organisation for Health Research and Development

    4. Oversight

    5. Study Description

    Brief Summary
    Previous epidemiological studies have shown that in cardiovascular patients, the 34C>T variant in the gene encoding for the enzyme Adenosine Mono Phosphate Deaminase (AMPD1) is associated with prolonged survival. The 34 C>T variant encodes a severely truncated, metabolically inactive protein. We hypothesize that during ischemia, in these patients AMP in preferentially converted into adenosine instead of IMP. Adenosine receptor stimulation, in turn, will increase resistance to ischemia-reperfusion in the myocardial tissue. To test this hypothesis, 7 male healthy volunteers heterozygous for the 34C>T variant will be selected from 100 healthy volunteers, which we have previously genotyped. These subjects will be compared with 7 matched control subjects. Individual ischemic tolerance will be assessed in the thenar muscle using 99mTc-Annexin A5 scintigraphy. Briefly, the circulation of the nondominant forearm will be interrupted for 10 minutes by inflation of an upperarm cuff to 200mmHg en concomitantly, the subjects will perform isometric rhythmic handgripping until exhaustion. Immediately upon reperfusion, 400 MBq of 99mTc-Annexin A5 will be administered intravenously. Finally, 1 and 4 hours post-injection, scintigrapghi imaging of both hand will be performed. Targeting of annexin A5 will be expressed as percentage difference between the experimental and control hand.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    AMPD, Ischemic Tolerance

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Single
    Allocation
    Non-Randomized
    Enrollment
    14 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    systemic administration of 99mTc-HYNIC-Annexin A5
    Intervention Type
    Behavioral
    Intervention Name(s)
    10 minutes of ischemic handgripping
    Primary Outcome Measure Information:
    Title
    99mTc-Annexin A5 targeting

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: male 18-40 years healthy AMPD1 34C>T variant (heterozygous) or matched control Exclusion Criteria: cardiovascular / pulmonary disease diabetes / hypertension
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gerard Rongen, MD, PhD
    Organizational Affiliation
    Radboud University Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance

    We'll reach out to this number within 24 hrs